Literature DB >> 35238366

Cost of Illness Due to Severe Enteric Fever in India.

Dilesh Kumar1, Atul Sharma2, Saroj Kumar Rana2, Shankar Prinja2, Karthikeyan Ramanujam1, Arun S Karthikeyan1, Reshma Raju1, Swathi Krishna Njarekkattuvalappil1, Prasanna S Premkumar1, Akashdeep Singh Chauhan2, Venkata Raghava Mohan1, Sheena Evelyn Ebenezer3, Mathew Santosh Thomas3, Madhu Gupta2, Ashita Singh4, Dasaratha Ramaiah Jinka5, Shajin Thankaraj6, Roshine Mary Koshy6, Christina Dhas Sankhro7, Arti Kapil8, Jayanthi Shastri9, Karnika Saigal10, Sulochana Putli Bai Perumal11, Savitha Nagaraj12, Shalini Anandan1, Maria Thomas13, Pallab Ray2, Jacob John1, Gagandeep Kang1.   

Abstract

BACKGROUND: Lack of robust data on economic burden due to enteric fever in India has made decision making on typhoid vaccination a challenge. Surveillance for Enteric Fever network was established to address gaps in typhoid disease and economic burden.
METHODS: Patients hospitalized with blood culture-confirmed enteric fever and nontraumatic ileal perforation were identified at 14 hospitals. These sites represent urban referral hospitals (tier 3) and smaller hospitals in urban slums, remote rural, and tribal settings (tier 2). Cost of illness and productivity loss data from onset to 28 days after discharge from hospital were collected using a structured questionnaire. The direct and indirect costs of an illness episode were analyzed by type of setting.
RESULTS: In total, 274 patients from tier 2 surveillance, 891 patients from tier 3 surveillance, and 110 ileal perforation patients provided the cost of illness data. The mean direct cost of severe enteric fever was US$119.1 (95% confidence interval [CI], US$85.8-152.4) in tier 2 and US$405.7 (95% CI, 366.9-444.4) in tier 3; 16.9% of patients in tier 3 experienced catastrophic expenditure.
CONCLUSIONS: The cost of treating enteric fever is considerable and likely to increase with emerging antimicrobial resistance. Equitable preventive strategies are urgently needed.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  India; cost of illness; economic burden; enteric fever; health expenditure; ileal perforation; out of pocket expenditure; typhoid

Mesh:

Year:  2021        PMID: 35238366      PMCID: PMC8892542          DOI: 10.1093/infdis/jiab282

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


Enteric fever is a public health concern in many low and middle-income countries (LMICs). In 2017, 14.3 million enteric fever episodes resulted in an estimated 178 000 deaths globally, with 70% in South Asia alone. Enteric fever was also the cause of 6 737 500 years of life lost in South Asia [1]. With the emergence of antimicrobial resistance and slow progress on water and sanitation interventions, the burden of enteric fever may increase [2, 3]. Typhoid vaccination could provide control of the disease until water, sanitation, and hygiene interventions reap dividends [4]. The World Health Organization (WHO) recommended introducing typhoid conjugate vaccine (TCV) in LMIC countries [5]. However, this requires substantial investment for these economies. With only 1.15% of gross domestic product public spending towards health care, India’s vaccination program has been slow to introduce new vaccines and relies heavily on out-of-pocket payments for treatment [6]. As India transitions out of Gavi Alliance support, a policy decision on introducing a new vaccine is urgent and necessitates substantial epidemiological and economic evidence of enteric fever burden [7-9]. Disease-specific spending in India is not well documented. There are very few data sources of individual health care expenditure, with only 3 studies reporting typhoid fever costs [10]. The Diseases of the Most Impoverished (DOMI) program reported that the total cost incurred by a hospitalized case to be US$129 [11]. In Kolkata, the average treatment cost of a hospitalized patient was US$99.36 in 2 hospitals [12]. In an urban slum in New Delhi, the mean total cost (patient and provider) of typhoid fever was US$126, with a hospitalized case costing much higher, US$636 [13]. Pooling these data has been challenging due to the different settings, health care facilities, and methodologies. Hence there was a need to assess the out-of-pocket burden of patients suffering from enteric fever in rural and urban areas. The Surveillance for Enteric Fever in India (SEFI) network was established to obtain reliable contemporaneous epidemiological data on enteric fever [14-16]. This article presents the out-of-pocket costs incurred by patients hospitalized with severe enteric fever and nontraumatic ileal perforation, a common complication of enteric fever [17], from the SEFI surveillance.

METHODS

Study Design and Setting

The SEFI network conducted surveillance at 18 sites across India for 2 years between November 2017 and March 2020. In tier 1 surveillance (4 sites), a large cohort of children younger than 15 years were followed for 24 months to measure the community incidence of typhoid fever. However, because the study supported the diagnostics and management of illness, tier 1 was not included in the cost estimation. The tier 2 surveillance was done in smaller hospitals in 5 rural sites and 1 urban site, combining facility-based surveillance with a health care utilization survey to estimate the incidence of severe enteric fever. The tier 3 surveillance was done in 8 key tertiary care hospitals in India. All blood culture-confirmed enteric fever patients in these hospitals were enrolled to assess patterns of enteric fever caused by Salmonella Typhi and Salmonella Paratyphi and estimate their antimicrobial resistance [14]. The 14 hospitals in tiers 2 and 3 captured cost of illness data for this study.

Data Collection

Severe enteric fever was defined as a hospitalized case with blood culture-confirmation for enteric fever. Nontraumatic ileal perforation was defined as a case diagnosed with ileal perforation by the operating surgeon. The economic data was obtained from the hybrid and laboratory surveillance using an incidence-based approach with an additional recall component for collecting pre- and posthospitalization costs using a structured questionnaire [18]. It included sociodemographic characteristics, income-expenditure details, illness-specific expenses, productive time lost, alternatives used for productivity, and related costs. Patients were followed up until 28 days to understand the costs incurred for the entire episode of illness. All collected information was entered electronically into a cloud-based server via a secure data management system. Data validation was done at the point of entry with inbuilt range and internal consistency checks. Simultaneously, the data management team performed standard logic checks and resolved issues using a closed query redressal system.

Data Analysis

Data analysis was done with Stata 15.1 software package. Incomplete data were excluded from the final analysis. All cost-related information was reported in Indian Rupees (Rs) and US dollars, wherein 2 January 2019 (mid-year of surveillance) currency conversion rate (1 US$ = Rs 69.6089) was applied [19]. The direct cost of 1 episode of severe enteric fever included hospitalization charges and outpatient charges pre- and posthospitalization. It comprises medical costs, including bed/consultation, diagnostic tests, procedure costs, prescribed medicines, and nonmedical costs such as food, transport, lodging, other expenses, and productive time lost by patients and caregivers. Indirect costs were computed from the patient and caregiver’s income loss and costs related to alternative productivity arrangements. The effective income loss was computed, assuming the patient or caregiver would work an 8-hour shift for 26 days a month. The total indirect cost was the sum of income lost and the payments related to alternate productivity used. Income lost was equal to the total time lost in professional work (hours) multiplied by the gross hourly income. All costs related to enteric fever were stratified by setting (tier 2/tier 3). However, nontraumatic ileal perforation costs were presented together, assuming costs would be similar across settings as it is often identified at surgery. Moreover, these ileal perforations were classified by 2 investigators (J. J. and S. K.) independently based on causality using available clinical data, laboratory evidence, and surgical or histopathological evidence. The cost for confirmed enteric ileal perforations were also presented [20]. Financial impact indicators such as distress financing and catastrophic health expenditure were computed. A household was said to be “distress financing” when they sourced their finances by borrowing (with or without interest) and selling assets [21, 22]. A household experienced catastrophic health expenditure if the household spent beyond 40% of their annual nonsubsistence expenditure on health care [23, 24]. Univariate analysis was done to explore the determinants of catastrophic health expenditure, while multivariate analysis was done to adjust for confounding.

Ethical Considerations

The institutional review boards of the Christian Medical College, Vellore, as the coordinating institution, and all participating institutions approved the study. All patient details were collected after obtaining written informed consent from the patient/caregiver.

RESULTS

Overall, 1275 patients provided costing information with 274 enteric fever patients from tier 2 sites, 891 from tier 3 sites, and 110 ileal perforation patients (n = 18 confirmed enteric fever perforations) from both tiers (Table 1). Of tier 2 and tier 3 patients, 31.1% and 62.9%, respectively, were younger than 15 years. More than 80% of the enteric fevers were due to S. Typhi in both settings. The mean duration of hospitalization was 5.6 days in tier 2, 7.95 days in tier 3, and 19.06 days among all-cause ileal perforation patients (Table 1).
Table 1.

Demographic Characteristics of Blood Culture-Confirmed Enteric Fever Patients Included in the Study (n = 1275)

CharacteristicsTier 2Tier 3Ileal Perforation, All-Cause
Total274891110
Organism
 Typhoid221 (80.7)782 (87.8)
 Paratyphoid53 (19.3)109 (12.2)
Age, y
 0–4 28 (10.2)228 (25.6)22 (20)
 5–14 60 (21.9)332 (37.3)8 (7.3)
 15–29 148 (54)243 (27.3)34 (30.9)
 30–44 33 (12)61 (6.8)20 (18.2)
 45–59
 ≥60 5 (1.8)27 (3)26 (23.6)
Sex
 Male176 (64.2)545 (61.2)70 (63.6)
 Female98 (35.8)346 (38.8)40 (36.4)
Duration of hospitalization, d, mean (95% CI)5.6 (5.25.9)7.95 (7.638.27)19.06 (16.5621.57)
Delay in hospitalization, d, mean (95% CI)7.2 (6.18.3)9.5 (8.410.6)11.3 (7.415.1)
Annual income, Rs, mean (95% CI)2 52 924.5 (2 22 006.5–2 83 842.4)4 80 806.1 (4 35 837.6–5 25 774.5)4 62 392.7 (3 49 387.7–5 75 397.8)
Annual expenditure, Rs, mean (95% CI)1 36 775.5 (1 27 120.4–1 46 430.7)2 43 832.6 (2 29 837.8–2 57 827.4)187 374.8 (1 60 526.6–2 14 222.9)
Capacity to pay, Rs, mean (95% CI)99 712.96 (90 804.2–10 8621.7)1 88 603.3 1 35 896.3
(1 75 087.3–2 02 119.4)(1 10 816.8–1 60 975.8)
Health insurance, yes43 (15.7)202 (22.7)2 (1.8)

Data are No. (%) except where indicated.

Abbreviation: CI, confidence interval; Rs, Indian Rupee.

Demographic Characteristics of Blood Culture-Confirmed Enteric Fever Patients Included in the Study (n = 1275) Data are No. (%) except where indicated. Abbreviation: CI, confidence interval; Rs, Indian Rupee. The mean direct cost of enteric fever was Rs8292.3 (US$119.1) in tier 2 settings, while the same in tier 3 was Rs28 237.7 (US$405.7) (Table 2). All-cause nontraumatic ileal perforation cost was Rs84 227.5 (US$1210) while those perforations confirmed to be enteric cause (n = 18) cost Rs90 869.2 (US$1305.4). Approximately three-quarters of these costs were during the hospital stay in all patients.
Table 2.

Distribution of Total Costs of Severe Enteric Fever

CostsTier 2, Rs (US$) (n = 274)Tier 3, Rs (US$) (n = 891)
MeanSEMeanSE
Direct medical costs
 User charges1626.6 (23.4)306.9 (4.4)9995.5 (143.6)463.0 (6.7)
 Diagnostic charges1402.2 (20.1)114.4 (1.6)5999.5 (86.2)270.3 (3.9)
 Drugs and consumables3168.3 (45.5)218.5 (3.1)6242.0 (89.7)496.8 (7.1)
 Procedure/surgery819.7 (11.8)663.9 (9.5)1279.3 (18.4)193.5 (2.8)
 Total direct medical costs7016.7 (100.8)1169.7 (16.8)23 516.2 (337.8)1087.9 (15.6)
Direct nonmedical costs
 Travel cost336.4 (4.8)39 (0.6)1233.6 (17.7)70.9 (1)
 Meal cost473.4 (6.8)34.5 (0.5)1347.6 (19.4)55.4 (0.8)
 Lodging charges6.2 (0.1)4.7 (0.1)117.0 (1.7)33.7 (0.5)
 Informal costs31 (0.4)11.1 (0.2)19.9 (0.3)6.4 (0.1)
 Other costs428.5 (6.2)40.1 (0.6)685.9 (9.9)34.1 (0.5)
 Total direct nonmedical costs1275.6 (18.3)84.9 (1.2)3404.1 (48.9)128.0 (1.8)
Uncategorized othersa1317.4 (18.9)687.9 (9.9)
Total direct cost8292.3 (119.1)1178 (16.9)28 237.7 (405.7)1373.4 (19.7)
Indirect cost
 Income lost by patient1653.2 (23.8)243 (3.5)3415.2 (49.1)510 (7.3)
 Income lost by caretakers2935.6 (42.2)234.3 (3.4)6972.7 (100.2)565.7 (8.1)
 Payment to substitute116.9 (1.7)58.6 (0.8)822.9 (11.8)321.4 (4.6)
 Total indirect cost4705.8 (67.6)318.8 (4.6)11 210.8 (161.1)982.1 (14.1)

Abbreviation: Rs, Indian Rupee; SE, standard error.

aUncategorized costs are costs wherein the patient/ bill carried only the total direct costs and therefore were left uncategorized.

Distribution of Total Costs of Severe Enteric Fever Abbreviation: Rs, Indian Rupee; SE, standard error. aUncategorized costs are costs wherein the patient/ bill carried only the total direct costs and therefore were left uncategorized. Among the determinants of expenditure, drugs and consumables were the highest in tier 2 (38.2%), while hospital charges like consultation, bed, and administrative charges formed the highest (35.4%) in tier 3 (Table 2). Children (<15 years) with enteric fever had lower expenses than adults in both settings (Table 3). Enteric fever patients with a private hospitalization spent at least 3 times as much as patients hospitalized in a public hospital in both settings. Patients who needed intensive care (Rs54 592.7/US$784.3) spent 8 times more than regular hospitalization in tier 2 settings (Table 3).
Table 3.

Total Direct Cost of Severe Enteric Fever by the Causative Organism, Age, Sex, and Sector

CharacteristicTier 2Tier 3
nMean, Rs (US$)nMean, Rs (US$)
Enteric Fever2748292.3 (119.1)89128 237.7 (405.7)
Organism
  Salmonella Typhi2219061.9 (130.2)78228 337.3 (407.1)
  Salmonella Paratyphi535083.7 (73)10927 523.3 (395.4)
Age, y
 <15 886975.7 (100.2)56018 396.2 (264.3)
 ≥ 15 1868915.3(128.1)33144 888.1 (644.9)
Sector
 Public sector1334308.8 (61.9)3319205.9 (132.3)
 Private/charity14112 049.8 (173.1)56039 486.9 (567.3)
Sex
 Male1767069.5 (101.6)54528 335.4 (407.1)
 Female9810 488.5 (150.7)34628 083.8 (403.5)
ICU admission
 No2646538.5 (93.9)82325 169.9 (361.6)
 Yes1054592.7 (784.3)6865 367.2 (939.1)
Outcome
 Recovered without complications2477008 (100.7)85728 043.9 (402.9)
 Sequelae/death/referred2321 722.9 (312.1)1268 443.3 (983.3)
Duration of stay, d
 ≤3 564582.8 (65.8)4815 170.2 (217.9)
 3–7 1687086.1 (101.8)49224 996.6 (359.1)
 >7 5016 500 (237)35134 567.8 (496.6)
Insurance
 No2318270.4 (118.8)68927 132.4 (389.8)
 Yes438410.1 (120.8)20232 007.7 (459.8)

Abbreviation: ICU, intensive care unit; Rs, Indian Rupee.

Total Direct Cost of Severe Enteric Fever by the Causative Organism, Age, Sex, and Sector Abbreviation: ICU, intensive care unit; Rs, Indian Rupee. The average productive time lost by the patient and caregivers together in different activities was 207 hours in tier 2, 263.5 hours in tier 3, and 535 hours for ileal perforations confirmed to be due to enteric fever. The indirect cost of enteric fever was Rs4705.8 (US$67.6) among patients in tier 2, while it was Rs11 210.8 (US$161.1) in tier 3 settings (Table 2). The indirect cost of ileal perforation of any cause was Rs26 488.2 (US$380.5) while the same among ileal perforations confirmed to be due to enteric fever was Rs46 770 (US$671.9). Patients with enteric fever predominantly used their salary or savings (73.7% and 65.7% in tier 2 and tier 3, respectively) to finance their treatment costs (Figure 1). No patients in tier 2 settings utilized health insurance, although 15.7% (n = 43) reported having some form of health insurance. In tier 3, 4.4% availed health insurance, although 22.7% (n = 202) reported having health insurance coverage. In tier 2 and tier 3 settings, 18.2% (n = 50) and 26.6% (n = 237), respectively, of the enteric fever patients were forced to distress finance their expenses (Figure 1). The costs for all-cause nontraumatic ileal perforation forced 39% of the households into distress financing their expenses while the costs due to confirmed enteric perforations forced 66.7% of the households into distress financing.
Figure 1.

Source of financing for severe enteric fever. Tier 2; surveillance in smaller hospitals in 5 rural sites and 1 urban site; tier 3, surveillance in 8 key tertiary care hospitals. *Four patients in tier 3 did not report their source of finance. †A person is said to be under distress financing when they spend by borrowing or selling of assets.

Source of financing for severe enteric fever. Tier 2; surveillance in smaller hospitals in 5 rural sites and 1 urban site; tier 3, surveillance in 8 key tertiary care hospitals. *Four patients in tier 3 did not report their source of finance. †A person is said to be under distress financing when they spend by borrowing or selling of assets. In tier 2, 35.4% (n = 97) of households spent over one-tenth of their nonsubsistence expenses on enteric fever treatment, while it was 54% (n = 481) of the households in tier 3 for the same (Figure 2). In tier 2 and tier 3 settings, 6.6% (n = 18) and 16.9% (n = 150), respectively, experienced catastrophic health expenditure (Figure 2). With regard to ileal perforations, 49.1% of the households with all-cause perforations and 61.1% of households with confirmed enteric fever as the cause experienced catastrophic health expenditure.
Figure 2.

Percentage of households spending above the cutoff on health care due to enteric fever. Distribution of direct medical expenses for enteric fever as a proportion of capacity to pay.. Catastrophic health expenditure was not computed for 1 subject with no expenses.

Percentage of households spending above the cutoff on health care due to enteric fever. Distribution of direct medical expenses for enteric fever as a proportion of capacity to pay.. Catastrophic health expenditure was not computed for 1 subject with no expenses. Multivariate analysis showed that, in both settings, hospitalization in the private sector compared to the public sector (tier 2, adjusted odds ratio [aOR], 12; 95% confidence interval [CI], 1.5–95.2: tier 3, aOR, 2.7; 95% CI, 1.7–4.3) and lowest income quintile compared to higher-income quintiles (tier 2, aOR, 7.0; 95% CI, 2.3–21.5: tier 3, aOR, 5.3; 95% CI, 3.5–8.2) had higher odds of experiencing financial catastrophe. Furthermore, families with lower than primary education (aOR, 7.6; 95% CI, 2.1–27.6) in tier 2 and patients older than 15 years (aOR, 2.9; 95% CI, 1.9–4.3) in tier 3 had a higher risk of catastrophic health expenditure compared to their counterparts (Table 4).
Table 4.

Determinants of Catastrophic Health Expenditure

Determinant Tier 2 (n = 274)Tier 3 (n = 890a)
n%Adjusted Odds Ratio P Valuen%Adjusted Odds Ratio P Value
Total186.615016.8
Highest education of the household
 Less than Primary628.67.56 (95% CI 2.0727.57).002Education details not collected in this surveillance
 More than Primary124.7Ref
Household size
 Up to 3 members23.84022.11.33 (95% CI 0.862.06).203
 More than 3 members167.211015.5Ref
Sector
 Public10.8Ref.019309.1Ref<.0001
 Private/Charity1712.112.02 (95% C 1.5295.19)12021.52.69 (95% CI 1.694.28)
Age, y
 <15 78.06511.6Ref<.0001
 ≥15 115.98525.82.87 (95% CI 1.914.3)
Sex
 Male105.79717.8
 Female88.25315.3
Insurance
 No146.111817.2
 Yes49.33215.8
Income quintile
 Q1, poorest1218.56.95 (95% CI 2.2521.52).0016033.35.31 (95% CI 3.458.17)<.0001
 Q2 and above 62.87Ref9012.7Ref

Univariate logistic regression was used to find early predictors and only those found to have an association was built into the regression model to identify predictors.

aCatastrophic health expenditure could not be computed for 1 patient in tier 3 as he/she did not report any expenses.

Determinants of Catastrophic Health Expenditure Univariate logistic regression was used to find early predictors and only those found to have an association was built into the regression model to identify predictors. aCatastrophic health expenditure could not be computed for 1 patient in tier 3 as he/she did not report any expenses.

Discussion

Overall, the direct cost of enteric fever requiring hospitalization was estimated to be US$119.1 in tier 2 surveillance and US$405.7 in tier 3 surveillance, which was higher than the DOMI study (2003) estimates from Kolkata, India (US$29) [11]. Similarly, the direct costs in tier 3 settings were higher than the total cost of typhoid fever requiring in-patient care from the Delhi study (1995–1996) done in urban slums. It is noted here that the total costs in the Delhi study included the patient costs and the cost borne by the health system [13]. Both these previous studies were >2 decades old, and health care costs are likely to have changed over this time. Studies from the Surveillance for Enteric Fever in Asia Project (SEAP 2016–2018) from Pakistan, Nepal, and Bangladesh (Ranged between US$ 168.72 - 316.94) done in teaching hospitals, reported slightly lower directs costs among inpatients and indirect costs comparable to our estimates from similar tier 3 surveillance (direct cost US$405.7; indirect cost US$161.1) [25-27]. These studies excluded medical costs that were not related to enteric fever. In our study all costs related to the Acute Febrile Illness were captured. Also, the use of telephonic data collection could run the risk of underestimating the costs in these studies. The cost of nontraumatic ileal perforation due to enteric fever has not been previously studied in India. Unsurprisingly this complication of enteric fever led to approximately 3 times the costs of a noncomplicated enteric fever in our study. This shows the direct costs for a hospitalized case of enteric fever could range from US$119.1 to US$1305.4, depending on the setting and severity. None of the tier 2 and only 4.4% (n = 39) of tier 3 patients could access health insurance for their treatment costs. The Rashtriya Swasthya Bima Yojana (RSBY) and Ayushman Bharath (AB-PMJAY-2018) are national schemes aimed to enable the “poorest 40 percent of the population to meet the expenses for quality secondary and tertiary care. Thereby it was aimed to reduce catastrophic expenditure and remove the financial risk arising out of such episodes” [28-31]. However, the study participants could not access these schemes and had to pay for care largely out of pocket. Consequently, 45% (n = 287) of enteric fever households resorted to distress financing. The lowest income quintile group in both the tiers (18.5% and 33.3%) had the highest proportion of catastrophic spending (Table 4). Therefore, national health insurance schemes need to expand coverage and enroll a wider network of health care providers to protect the poor. Universal health insurance schemes and universal basic income approaches could pave the way for equitable access to health care and also reduce impoverishment in the country. Patients who sought care in the private sector had 3 times greater expenditure compared to the public sector and therefore had higher odds (aOR, 12.0 and 2.7 for tier 2 and tier 3, respectively) of experiencing catastrophic health expenditure. The cost of treatment for enteric fever requiring hospitalization in tier 3 (US$405.7) was higher than the cost of dengue hospitalization (US$197.03) in teaching hospitals in India [32]. This shows that enteric fever treatment is expensive and results in high out-of-pocket payments, similar to ailments due to other infectious causes. The data collected through the SEFI study shows that out-of-pocket patient expenditure for the treatment of enteric fever in India remains high in both tiers. The disease continues to disproportionately coerce households into financial catastrophe. To prevent this, control measures against the disease, such as the typhoid conjugate vaccines, must be deployed after appropriate cost-effectiveness studies. Our study is the first large study to report patient-level costs of enteric fever requiring hospitalization in India, studying costs from 1275 patients from 14 sites. Previous studies in India were from 1 or 2 sites, and the costs were derived from a significantly lower study sample [11, 13]. There were limitations to the study. Firstly, while we attempted to represent the costs in different risk settings, we recognize the limitation in being truly representative of the country. This study does not provide adequate information on the costs related to enteric fever in very poor urban slums where most patients tend to get treated in informal care as outpatients with prophylactic antibiotics. Secondly, we recognize that a variable proportion of health care costs are absorbed by the health system in both the government and private charitable facilities, and a comprehensive economic burden requires estimation of the health system costs. However, collecting costs from health care providers require multiple levels of approval, particularly in the government sector. Therefore, these costs were not computed and our focus remained predominantly on out-of-pocket expenditure. Further, consumption expenditure details obtained in our study might be affected by recall bias as participants were required to provide their last month’s complete expense details. Also, we assumed an 8-hour schedule of work per day for computation of indirect costs and did not collect actual work timings. We did not monetize wages for children, unemployed, and homemakers, which could underestimate the indirect cost of the disease.

CONCLUSION

This study shows that out-of-pocket expenses for enteric fever are high in urban areas and for hospitalizations. Patients and their households bear high indirect costs, particularly detrimental for those from lower strata who access public services intended to provide free health care. The study shows that enteric fever continues to push families into impoverishment and that the government health insurance schemes for the poor have not proven very effective in averting their financial risk. It is hoped that these results will help build a case for developing and implementing effective control measures to minimize the effects it bears on enteric fever patients due to out-of-pocket expenditures.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
  26 in total

1.  Cost of illness due to typhoid fever in five Asian countries.

Authors:  Christine Poulos; Arthorn Riewpaiboon; John F Stewart; John Clemens; Soyeon Guh; Magdarina Agtini; Dang Duc Anh; Dong Baiqing; Zulfiqar Bhutta; Dipika Sur; Dale Whittington
Journal:  Trop Med Int Health       Date:  2011-01-12       Impact factor: 2.622

2.  Borrowing and selling to pay for health care in low- and middle-income countries.

Authors:  Margaret E Kruk; Emily Goldmann; Sandro Galea
Journal:  Health Aff (Millwood)       Date:  2009 Jul-Aug       Impact factor: 6.301

3.  Opportunities for Typhoid Vaccination in India.

Authors:  Manikandan Srinivasan; Kulandaipalayam Natarajan Sindhu; Jacob John; Gagandeep Kang
Journal:  Indian Pediatr       Date:  2019-06-15       Impact factor: 1.411

4.  Extending health insurance to the poor in India: An impact evaluation of Rashtriya Swasthya Bima Yojana on out of pocket spending for healthcare.

Authors:  Anup Karan; Winnie Yip; Ajay Mahal
Journal:  Soc Sci Med       Date:  2017-03-27       Impact factor: 4.634

5.  The Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) Population-based Enteric Fever Studies: A Review of Methodological Similarities and Differences.

Authors:  Megan E Carey; William R MacWright; Justin Im; James E Meiring; Malick M Gibani; Se Eun Park; Ashley Longley; Hyon Jin Jeon; Caitlin Hemlock; Alexander T Yu; Abdramane Soura; Kristen Aiemjoy; Ellis Owusu-Dabo; Mekonnen Terferi; Sahidul Islam; Octavie Lunguya; Jan Jacobs; Melita Gordon; Christiane Dolecek; Stephen Baker; Virginia E Pitzer; Mohammad Tahir Yousafzai; Susan Tonks; John D Clemens; Kashmira Date; Firdausi Qadri; Robert S Heyderman; Samir K Saha; Buddha Basnyat; Iruka N Okeke; Farah N Qamar; Merryn Voysey; Stephen Luby; Gagandeep Kang; Jason Andrews; Andrew J Pollard; Jacob John; Denise Garrett; Florian Marks
Journal:  Clin Infect Dis       Date:  2020-07-29       Impact factor: 9.079

Review 6.  A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines.

Authors:  K Luthra; E Watts; F Debellut; C Pecenka; N Bar-Zeev; D Constenla
Journal:  Clin Infect Dis       Date:  2019-03-07       Impact factor: 9.079

7.  Out-of-pocket expenditure and catastrophic health expenditure for hospitalization due to injuries in public sector hospitals in North India.

Authors:  Shankar Prinja; Jagnoor Jagnoor; Deepshikha Sharma; Sameer Aggarwal; Swati Katoch; P V M Lakshmi; Rebecca Ivers
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

8.  Typhoid and Paratyphoid Cost of Illness in Pakistan: Patient and Health Facility Costs From the Surveillance for Enteric Fever in Asia Project II.

Authors:  Nelly Mejia; Farah Qamar; Mohammad T Yousafzai; Jamal Raza; Denise O Garrett; Kashmira Date; Taiwo Abimbola; Sarah W Pallas
Journal:  Clin Infect Dis       Date:  2020-12-01       Impact factor: 9.079

9.  Treatment cost for typhoid fever at two hospitals in Kolkata, India.

Authors:  Dipika Sur; Susmita Chatterjee; Arthorn Riewpaiboon; Byomkesh Manna; Suman Kanungo; Sujit K Bhattacharya
Journal:  J Health Popul Nutr       Date:  2009-12       Impact factor: 2.000

10.  Longitudinal Typhoid Fever Trends in India from 2000 to 2015.

Authors:  Veeraraghavan Balaji; Arti Kapil; Jayanthi Shastri; Agila Kumari Pragasam; Geeta Gole; Sirshendu Choudhari; Gagandeep Kang; Jacob John
Journal:  Am J Trop Med Hyg       Date:  2018-07-24       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.